Edition:
India

Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease


Tuesday, 9 Jun 2020 

June 8 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS INC - NEW DRUG APPLICATION SUBMISSION PLANNED BY MID-2021.GLOBAL BLOOD THERAPEUTICS - TO SUBMIT NDA FOR OXBRYTA FOR TREATMENT OF SCD IN CHILDREN AGES 4 TO 11 YEARS UNDER FDA'S ACCELERATED APPROVAL PATHWAY.